Updated Version COVID-19 Vaccine

In partnership with

FDA Approved Updated Version COVID-19 Vaccine: Summer Surge

The Food and Drug Administration (FDA) has granted emergency use authorization for an updated version of the Novavax COVID-19 vaccine in response to the recent summer surge in infections.

This updated vaccine is designed to better target circulating variants and offers enhanced protection against severe outcomes of the virus, such as hospitalization and death. It is now approved for individuals aged 12 and older and specifically addresses the JN.1 strain, according to the FDA’s announcement.

4 Million People Found Peace with BetterHelp – What’s Stopping You?

Do you find yourself stuck in a loop of worry and self-doubt? You’re not alone. Millions struggle with these thoughts, but you don’t have to. BetterHelp therapists specialize in helping clients change unhelpful thinking patterns and build healthier habits. Answer a free 5-minute quiz to get matched with a therapist today and start therapy from your phone, computer, or through text. Plus, use your FSA/HSA dollars to cover therapy and enjoy 30% off your first three months. Don’t wait—take control of your mental health now.

Claim 30% Off

Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research, emphasized the importance of COVID-19 vaccines in public health, stating that vaccination remains the most effective method for preventing the virus. He advised eligible individuals to get the updated vaccine.

“This authorization provides another COVID-19 vaccine option that meets our rigorous standards for safety, effectiveness, and manufacturing quality,” Marks said.

This approval follows earlier announcements of updated vaccines from Pfizer and Moderna, which target the KP.2 strain of the SARS-CoV-2 virus.

Although COVID-19 is no longer classified as a pandemic, experts warn that it is likely to persist. The Centers for Disease Control and Prevention (CDC) reported on August 16 that COVID-19 infections are increasing or are expected to increase in 27 states. The predominant strain was P.3.1.1, accounting for 42.2% of cases over the two weeks ending August 31. The JN.1 strain was present in 0.2% of cases, while the KP.2 strain was at 3.1%.

Currently circulating variants are mostly causing symptoms such as chills, fever, runny nose, and congestion, according to Cedar Sinai.